Cell-Free DNA are fragments of DNA which circulate in the blood fluid and can be utilized as valuable biomarkers. It is a new technology in which small quantity of liquid sample (saliva, urine, or blood) from the patient is collected to examine the freely flowing DNA. Cell-Free DNA (cfDNA) is a noninvasive screening test used to help detect graft rejection, identify mutations in cancer patients and detect various chromosomal abnormalities in the fetus, to know the gender of the fetus. The discovery of cfDNA has opened up to new potentials in the field of oncology, gynecology, transplantation and infectious diseases.Ê
Scope of the Report:This report studies the Cell-Free DNA (cfDNA) Testing market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cell-Free DNA (cfDNA) Testing market by product type and applications/end industries.
Increased incidences of diseases like chromosomal abnormalities due to increasing maternal age, changing lifestyle, unhealthy diet habits and rising prevalence of cancer, also in addition to it increasing healthcare expenditure, and rising healthcare awareness are the reasons driving the cell-free DNA market.
The global Cell-Free DNA (cfDNA) Testing market is valued at xx million USD in 2020 and is expected to reach xx million USD by the end of 2026, growing at a CAGR of xx% between 2020 and 2026.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cell-Free DNA (cfDNA) Testing.
Europe also play important roles in global market, with market size of xx million USD in 2020 and will be xx million USD in 2026, with a CAGR of xx%.
Market Segment by Companies, this report covers Agilent Technology
Allenex
Biocept
Biodesix
CareDx
Guardant Health
Illumania
Invited
Natera
Quest Diagnostics
Roche Holdings
Sequenom
Trovagene
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers Donor-Derived Cell-Free DNA (DdcfDNA)
Circulating Cell-Free Tumor DNA (CtDNA)
Cell-Free Fetal DNA (NIPT)
Market Segment by Applications, can be divided into Hospital
Ambulatory Surgical Centers
Cancer Research Institutes
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
